Recent studies have emphasised that the majority of patients with the onset of epilepsy in adult life can satisfactorily be managed by using a single anticonvulsant drug. ' There is little definite evidence that adding a second anticonvulsant drug improves seizure control in patients who have received an optimal dose of a single drug. 24 Since the risks of adverse reactions and chronic toxicity increase when multiple anticonvulsant drugs are administered,45 monotherapy has become increasingly popular. This poses a question that has not previously demanded serious investigation, namely: which anticonvulsant drug to choose for an individual patient?
Three major factors are likely to influence the choice of an anticonvulsant: efficacy, toxicity and cost. In clinical practice assumptions made about comparative efficacy of anticonvulsants have been of major importance in this choice, and it is the purpose of this review to question the basis for these assumptions.
The desire to adopt a universally acceptable classification of both seizures and epilepsy stems in part with seizure frequency following the initiation or change of therapy, and using percentage change to define the response as "good", "poor" etc. However, there may be inherent difficulties in such comparisons. Patients rarely have a stable seizure threshold and seizures not infrequently occur in clusters. Thus when a patient presents with a flurry of four seizures within one week and has his or her treatment amended it might be assumed that the pre-treatment seizure frequency might amount to some 16 seizures per month. However the patient may only experience one such flurry of seizures in a year, in which case when treatment is started the apparent monthly seizure frequency might well fall from twelve seizures per month, to 0-35 seizures per month even if the drug treatment had no effect on seizure frequency. It is therefore necessary in assessing treatment to ensure that the period of observation prior to treatment is prolonged and identical to the period following the change before comparisons of seizure frequency can be derived.
In previously untreated patients it may be difficult to withhold a treatment to establish a pretreatment seizure frequency so that other means of assessing seizure response become necessary in such patients. Here it seems preferable to adopt definitions of control of epilepsy which describe periods entirely free from seizures. In this instance control of epilepsy may be defined in terms of the number of patients entering remissions lasting, one, two or more years."' Such a definition is more clinically relevant than any assessment based on comparisons of seizure frequencies, clinicians and patients aiming for complete cessation of attacks, rather than reduction of say 50% from four seizures per day, to two.
Patient selection
Studies of anticonvulsant efficacy have usually been undertaken in chronic epileptic patients who have proved themselves resistant to therapy over many years, and who often continue with their previous medication during the drug study. The long-term remission rates in such patients are always likely to remain low, in contrast to the prognosis for newly diagnosed patients with epilepsy in whom the prognosis is considerably better.'°0 Indeed when a trial drug is given as add-on therapy to patients with chronic epilepsy, whose seizures continue in spite of one, two, or more drugs in combination, the lack of response to an additional drug may not imply a lack of anticonvulsant properties. It may simply be an indication that the trial drug is no more effective than the previously administered drugs, or that the trial drug has a similar mechanism of action to the concurrently administered drugs.
These considerations make it essential that comparative studies of the efficacy and toxicity of anticonvulsant drugs should rely on trial designs which include a randomisation procedure with prolonged follow-up. Multiple drug therapy should be avoided, and the population of patients should be defined in terms of those factors known to influence prognosis. (table 4) . However, these usually give no information to confirm that the groups as randomised are comparable for those factors known to influence the prognosis of epilepsy, '2 essential for this particular type of design, which lacks a cross-over. In spite of these difficulties it is nevertheless quite striking that only one study'" suggests that one of the anticonvulsant drugs tested was superior to another, phenytoin being preferred to sulthiame. As some of the antiepileptic properties of sulthiame may be due to its ability to inhibit phenytoin metabolism,'4 it is perhaps not surprising that the drug is inferior when compared to phenytoin.
Three recently reported studies demand further comment, as they were undertaken in previously untreated patients who were randomised to different drugs shortly after the diagnosis of epilepsy. Callaghan et all-compared phenytoin, carbamazepine, and valproate in 181 adult patients with tonic-clonic or partial seizures who were followed up for a mean of 20 months. Whilst the criteria for seizure control were inadequate (see above), the drugs were found equally effective with the exception that phenytoin therapy was more likely to result in excellent control of tonic-clonic seizures (freedom from attacks for a mean of 3 months), than carbamazepine. Loiseau et al" used a response-conditional cross-over comparative study of carbamazepine and valproate in 31 patients with newly diagnosed partial epilepsy. Whilst the numbers are small and follow-up short no differences were detected between efficacy of valproate and carbamazepine. Turnbull et al '' Gowers'8 commented that 83% of his patients presenting with a history of epilepsy of less than one year's duration would be "cured" by treatment with bromides. This is strikingly similar to claims made for drug therapy at present. ' ' ' 1 Furthermore, there is a striking similarity between those factors which predict the onset of remission of epilepsy during drug therapy and those factors which predict the likelihood of continued remission if anticonvulsants are withdrawn after a prolonged period of seizure control.", One possible explanation of this might be that onset of remission is to some degree co-incidental to drug therapy in those patients who continue in remission after the withdrawal of drugs.
In essence it seems that epilepsy has a spectrum of severity. At one extreme are patients with only a few tonic-clonic seizures as part of an idiopathic epilepsy, who will respond well irrespective of the potency of the chosen drug. Indeed, some patients may arguably not require drug therapy. At the other extreme are patients with partial or secondary generalised epilepsies, symptomatic of cerebral disease, and complicated by neuropsychiatric handicap who are unlikely to be controlled by any available antiepileptic drug or combinations of drugs. There may only be a small number of patients between these extremes in whom the choice of drug influences outcome. As such patients cannot presently be identified, comparative studies of antiepileptic drugs will have to include larger numbers of patients to detect differences in efficacy.
There is an obvious need for further large, longterm randomised comparisons of anticonvulsant drugs, preferably in previously untreated patients. One adequate study has recently been reported. '7 Similar studies have been commenced in both this country and the USA, and the results will be of considerable importance.
In conclusion, at present it is impossible, on the Chadwick, Turnbull basis of controlled randomised comparisons of anticonvulsant drugs, to suggest that any individual drug is to be preferred in terms of its therapeutic efficacy against tonic-clonic or partial seizures in adult patients. In these circumstances the choice of drug should be determined by the comparative toxicity, and the cost of drug therapy.
